Sherim Squibss Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 6 Year, 4 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 5.84 M
- Revenue Growth 48.99%
- Profit Growth 71.38%
- Ebitda 110.42%
- Net Worth 79.45%
- Total Assets 53.11%
About Sherim Squibss Pharma
Sherim Squibss Pharma Private Limited (SSPPL) is a registered startup operating as a Private Limited Indian Non-Government Company incorporated in India on 11 September 2018 (Six years and four months 23 days old ). Its registered office is in Amritsar, Punjab, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹5.84 M.
Rishab Kapoor and Pawan Kapoor serve as directors at the Company.
Company Details
-
Location
Amritsar, Punjab, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U51909PB2018PTC048339
-
Company No.
048339
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
11 Sep 2018
-
Date of AGM
30 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Chandigarh
Industry
Who are the key members and board of directors at Sherim Squibss Pharma?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rishab Kapoor
|
Director | 11-Sep-2018 | Current |
|
Pawan Kapoor
|
Director | 11-Sep-2018 | Current |
Financial Performance of Sherim Squibss Pharma.
Sherim Squibss Pharma Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 48.99% increase. The company also saw a substantial improvement in profitability, with a 71.38% increase in profit. The company's net worth Soared by an impressive increase of 79.45%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Sherim Squibss Pharma?
In 2023, Sherim Squibss Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Recxia Formulations Private LimitedPawan Kapoor is a mutual person
Charges (Loans)
₹5.84 M
₹0
Charges Breakdown by Lending Institutions
- Hdfc Bank Limited : 0.35 Cr
- Bank Of India : 0.24 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 13 Feb 2023 | Bank Of India | ₹2.35 M | Open |
| 07 Sep 2022 | Hdfc Bank Limited | ₹3.49 M | Open |
How Many Employees Work at Sherim Squibss Pharma?
Sherim Squibss Pharma has a workforce of 29 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sherim Squibss Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sherim Squibss Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.